0001437749-24-009990.txt : 20240329 0001437749-24-009990.hdr.sgml : 20240329 20240329110059 ACCESSION NUMBER: 0001437749-24-009990 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240329 DATE AS OF CHANGE: 20240329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NovaBay Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001389545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 680454536 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-33678 FILM NUMBER: 24802575 BUSINESS ADDRESS: STREET 1: 2000 POWELL STREET, SUITE 1150 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: (510) 899-8800 MAIL ADDRESS: STREET 1: 2000 POWELL STREET, SUITE 1150 CITY: EMERYVILLE STATE: CA ZIP: 94608 10-K/A 1 nby20231231_10ka.htm FORM 10-K/A nby20231231_10ka.htm
true 0001389545 0001389545 2023-01-01 2023-12-31 0001389545 2023-06-30 0001389545 2024-03-21 iso4217:USD xbrli:shares
 
 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-K/A
Amendment No. 1
 
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the fiscal year ended December 31, 2023
--12-31FY2023
 
OR
 
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from                     to
 
Commission file number 001-33678
 
NOVABAY PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
68-0454536
(State or other jurisdiction of incorporation or
organization)
(I.R.S. Employer Identification No.)
 
2000 Powell Street, Suite 1150, Emeryville, California 94608
(Address of principal executive offices) (Zip Code)
 
Registrant's Telephone Number, Including Area Code: (510) 899-8800
 
Securities Registered Pursuant to Section 12(b) of the Act:
 
Title of Each Class
Trading Symbol(s)
Name of Each Exchange On Which Registered
Common Stock, par value $0.01 per share
NBY
NYSE American
 
Securities Registered Pursuant to Section 12(g) of the Act: None.
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. 
Yes ☐    No ☒
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. 
Yes ☐    No ☒
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒    No ☐
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
 
 
 
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
 
Large accelerated filer 
☐
Accelerated filer 
☐
Emerging growth company
☐
Non-accelerated filer
☒
Smaller reporting company 
☒
    
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act by the registered public accounting firm that prepared or issued its audit report. ☐
 
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
 
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No ☒
 
As of June 30, 2023, the aggregate market value of the voting stock held by non-affiliates of the registrant, computed by reference to the last sale price of such stock as of such date on the NYSE American, was approximately $3,050,485. This figure excludes an aggregate of 159,265 shares of common stock held by affiliates, including officers and directors, as of June 30, 2023. Exclusion of shares held by any of these persons should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant, or that such person is controlled by or under common control with the registrant.
 
As of March 21, 2024, there were 30,098,150 shares of the registrant’s common stock outstanding.
 
Auditor firm ID Auditor Name Auditor Location
PCAOB ID No. 100 WithumSmith+Brown, PC San Francisco, California
 
DOCUMENTS INCORPORATED BY REFERENCE
 
None.
 
 
 
 
EXPLANATORY NOTE
 
This Amendment No. 1 on Form 10-K/A (this “Amendment”) amends the Annual Report on Form 10-K of NovaBay Pharmaceuticals, Inc. for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 26, 2024 (the “Original Filing”). Exhibit 4.1 (Description of Securities) (the “Description of Securities”) was inadvertently omitted in the Original Filing.
 
This Amendment is being filed solely to file the Description of Securities. No other changes were made to the Original Filing. Further, no attempt has been made in this Amendment to modify or update the other disclosures presented in the Original Filing. This Amendment does not reflect events occurring after the filing of the Form 10-K (i.e., occurring after March 26, 2024) or modify or update those disclosures that may be affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the Original Filing and the registrant’s other filings with the Securities and Exchange Commission.
 
In accordance with Rule 12b-15 of the Securities Exchange Act of 1934, as amended, this Amendment includes new certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, as amended, dated as of the filing date of this Amendment.
 
 
 
 
PART IV
 
ITEM 15.
EXHIBITS, FINANCIAL STATEMENT SCHEDULES
 
(a) Documents filed as part of this report:
 
(1) Financial Statements. financial statements are not included in this Amendment. See the consolidated financial statements of NovaBay Pharmaceuticals, Inc. included in Part II, Item 8 of the Original Filing.
 
(2) Financial Statement Schedules. All schedules have been omitted because they are not required or the required information is included in our consolidated financial statements and notes thereto.
 
(3) Exhibits. The following exhibits are filed as part of this Report:
 
 
Incorporation by Reference
Filed
Herewith
Exhibit
Number
Exhibit Description
Form
File
Number
Exhibit/
Form 8-K
Item
Reference
Filing
Date
  
2.1
8-K
001-3678
2.1
9/28/2021
  
2.2
8-K
001-3678
2.1
03/14/2024
  
3.1
10-K
001-33678
3.1
3/21/2018
  
3.2
8-K
001-33678
3.1
6/04/2018
  
3.3
8-K
001-33678
3.1
5/28/2020
  
3.4
8-K
001-33678
3.1
5/24/2021
  
3.5
8-K
001-33678
3.1
2/1/2022
  
3.6
8-K
001-33678
3.1
11/18/2022
  
3.7
8-K
001-33678
3.1
11/1/2021
  
3.8
8-K
001-33678
3.2
11/18/2022
  
3.9
10-K
001-33678
3.7
6/14/2023
  
4.1
10-K
001-33678
4.1
3/31/2023
  
4.2
8-K
001-33678
4.1
5/18/2020
  
4.3
8-K
001-33678
4.1
7/21/2020
  
4.4
8-K
001-33678
4.1
9/13/2022
  
4.5
8-K
001-33678
4.2
9/13/2022
  
4.6
8-K
001-33678
4.3
9/13/2022
  
4.7
8-K
001-33678
4.4
9/13/2022
  
4.8
8-K
001-33678
4.5
9/13/2022
  
4.9
8-K
001-33678
4.6
9/13/2022
  
4.10
8-K
001-33678
4.1
4/27/2023
  
4.11
8-K
001-33678
4.2
4/27/2023
  
 
 
 
 
4.12
8-K
001-33678
4.3
4/27/2023
  
4.13
8-K
001-33678
4.4
4/27/2023
  
4.14
8-K
001-33678
4.1
12/21/2023
  
4.15
8-K
001-33678
4.2
3/25/2024
  
4.16
8-K
001-33678
4.3
3/25/2024
  
10.1
10-K
001-33678
10.1
3/29/2022
  
10.2+
S-8
333-215680
99.1
1/24/2017
  
10.3+
S-8
333-218469
99.1
6/02/2017
  
10.4+
S-8
333-218469
99.2
6/02/2017
  
10.5+
8-K
001-33678
10.1
2/6/2020
  
10.6+
8-K
001-33678
10.6
1/28/2022
  
10.7+
8-K
001-33678
10.3
12/11/2023
  
10.8+
10-K
001-33678
10.8
3/26/2024
  
10.9
8-K
001-33678
10.1
8/26/2016
  
10.10
8-K
001-33678
10.2
1/28/2022
  
10.11†
10-K
001-33678
10.18
3/27/2012
  
10.12
8-K
001-33678
1.1
5/14/2021
  
10.13
8-K
001-33678
10.1
7/21/2020
  
10.14
8-K
001-33678
10.2
7/21/2020
  
10.15
8-K
001-33678
10.3
7/21/2020
  
10.16
8-K
001-33678
1.1
11/01/2021
  
10.17
8-K
001-33678
10.1
11/01/2021
  
10.18
8-K
001-33678
10.1
9/13/2022
  
10.19
8-K
001-33678
10.2
9/13/2022
  
10.20
8-K
001-33678
10.3
9/13/2022
  
10.21
8-K
001-33678
10.4
9/13/2022
  
10.22+
8-K
001-33678
10.8
3/31/2023
  
10.23
8-K
001-33678
10.1
12/21/2023
  
10.24*
8-K
001-33678
10.1
1/05/2024
  
10.25
8-K
001-33678
10.1
4/27/2023
  
10.26*
8-K
001-33678
10.2
4/27/2023
  
10.27*
8-K
001-33678
10.3
3/25/2024
  
10.28
8-K
001-33678
10.3
4/27/2023
  
10.29*
8-K
001-33678
10.4
3/25/2024
  
 
 
 
 
10.30
8-K
001-33678
10.4
4/27/2023
  
10.31
8-K
001-33678
10.5
4/27/2023
  
21
10-K
001-33678
21
3/26/2024
  
23.1
10-K
001-33678
23.1
3/26/2024
  
31.1
        
X
31.2
        
X
32.1
        
X
32.2
        
X
97
10-K 
001-33678
97
3/26/2024
  
101.INS
Inline XBRL Instance Document
        
X
101.SCH
Inline XBRL Taxonomy Extension Schema Document 
        
X
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document
        
X
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase
        
X
101.LAB
Inline XBRL Taxonomy Extension Labels Linkbase Document
        
X
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document
        
X
104
The Cover Page Interactive Data File, formatted in Inline XBRL (included within the Exhibit 101 attachments)
        
X
 
+
Indicates a management contract or compensatory plan or arrangement
†
NovaBay Pharmaceuticals, Inc. has been granted confidential treatment with respect to certain portions of this exhibit (indicated by asterisks), which have been separately filed with the Securities and Exchange Commission.
*
Certain confidential portions of this exhibit were omitted by means of marking such portions with brackets because the confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Form 10-K/A to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
Date: March 29, 2024
  
 
By:
/s/   Justin Hall 
   
Justin Hall 
Chief Executive Officer, General Counsel and Director
(principal executive officer)
 
 
 EX-31.1 2 ex_647372.htm EXHIBIT 31.1 ex_647372.htm

Exhibit 31.1

 

CERTIFICATION PURSUANT TO EXCHANGE ACT

RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Justin Hall, certify that:

 

1. I have reviewed this Form 10-K/A of NovaBay Pharmaceuticals, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

Date: March 29, 2024

 

/s/ Justin Hall

  

Justin Hall

  

Chief Executive Officer, General Counsel

and Director (principal executive officer)

  

 

 
 EX-31.2 3 ex_647369.htm EXHIBIT 31.2 ex_647369.htm

Exhibit 31.2

 

CERTIFICATION PURSUANT TO EXCHANGE ACT

RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Tommy Law, certify that:

 

1. I have reviewed this Form 10-K/A of NovaBay Pharmaceuticals, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

Date: March 29, 2024

 

/s/ Tommy Law

  

Tommy Law

  

Interim Chief Financial Officer

  

(principal financial officer)

  

 

 
 EX-32.1 4 ex_647370.htm EXHIBIT 32.1 ex_647370.htm

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the annual report of NovaBay Pharmaceuticals, Inc. (the Company) on Form 10-K/A for the fiscal year ended December 31, 2023 (the Report), I, Justin Hall, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 29, 2024

 

/s/ Justin Hall 

  

Justin Hall

  

Chief Executive Officer, General Counsel

and Director

  

 

This Certification is made solely for the purpose of 18 USC Section 1350, subject to the knowledge standard contained therein, and not for any other purpose.

 

 
 EX-32.2 5 ex_647371.htm EXHIBIT 32.2 ex_647371.htm

Exhibit 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the annual report of NovaBay Pharmaceuticals, Inc. (the Company) on Form 10-K/A for the fiscal year ended December 31, 2023 (the Report), I, Tommy Law, Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 29, 2024

 

/s/ Tommy Law

  

Tommy Law

Interim Chief Financial Officer

 

This Certification is made solely for the purpose of 18 USC Section 1350, subject to the knowledge standard contained therein, and not for any other purpose.

 

 
 EX-101.SCH 6 nby-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 7 nby-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 nby-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Annual Report Document, Period End Date Current Fiscal Year End Date Document, Fiscal Period Focus Document, Fiscal Year Focus Document, Transition Report Entity, File Number Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Well-known Seasoned Issuer Entity, Voluntary Filers Entity, Current Reporting Status Entity, Interactive Data, Current Entity, Emerging Growth Company Entity, Filer Category Entity, Small Business ICFR Auditor Attestation Flag Document, Financial Statement Error Correction Flag Entity, Shell Company Entity, Public Float Entity, Common Stock Shares, Outstanding Auditor Firm ID Auditor Name Auditor Location Amendment Description Amendment Flag Entity, Central Index Key EX-101.PRE 9 nby-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2023
Mar. 21, 2024
Jun. 30, 2023
Document Information [Line Items]      
Entity, Registrant Name NOVABAY PHARMACEUTICALS, INC.    
Document, Type 10-K/A    
Document, Annual Report true    
Document, Period End Date Dec. 31, 2023    
Current Fiscal Year End Date --12-31    
Document, Fiscal Period Focus FY    
Document, Fiscal Year Focus 2023    
Document, Transition Report false    
Entity, File Number 001-33678    
Entity, Incorporation, State or Country Code DE    
Entity, Tax Identification Number 68-0454536    
Entity, Address, Address Line One 2000 Powell Street, Suite 1150    
Entity, Address, City or Town Emeryville    
Entity, Address, State or Province CA    
Entity, Address, Postal Zip Code 94608    
City Area Code 510    
Local Phone Number 899-8800    
Title of 12(b) Security Common Stock    
Trading Symbol NBY    
Security Exchange Name NYSE    
Entity, Well-known Seasoned Issuer No    
Entity, Voluntary Filers No    
Entity, Current Reporting Status Yes    
Entity, Interactive Data, Current Yes    
Entity, Emerging Growth Company false    
Entity, Filer Category Non-accelerated Filer    
Entity, Small Business true    
ICFR Auditor Attestation Flag false    
Document, Financial Statement Error Correction Flag false    
Entity, Shell Company false    
Entity, Public Float     $ 3,050,485
Entity, Common Stock Shares, Outstanding   30,098,150  
Auditor Firm ID 100    
Auditor Name WithumSmith+Brown, PC    
Auditor Location San Francisco, California    
Amendment Description This Amendment No. 1 on Form 10-K/A (this “Amendment”) amends the Annual Report on Form 10-K of NovaBay Pharmaceuticals, Inc. for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 26, 2024 (the “Original Filing”). Exhibit 4.1 (Description of Securities) (the “Description of Securities”) was inadvertently omitted in the Original Filing.   This Amendment is being filed solely to file the Description of Securities. No other changes were made to the Original Filing. Further, no attempt has been made in this Amendment to modify or update the other disclosures presented in the Original Filing. This Amendment does not reflect events occurring after the filing of the Form 10-K (i.e., occurring after March 26, 2024) or modify or update those disclosures that may be affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the Original Filing and the registrant’s other filings with the Securities and Exchange Commission.   In accordance with Rule 12b-15 of the Securities Exchange Act of 1934, as amended, this Amendment includes new certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, as amended, dated as of the filing date of this Amendment.    
Amendment Flag true    
Entity, Central Index Key 0001389545    
EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 3 38 1 false 0 0 false 2 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.nby.com/20231231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports nby-20231231.xsd nby-20231231_def.xml nby-20231231_lab.xml nby-20231231_pre.xml nby20231231_10ka.htm http://xbrl.sec.gov/dei/2023 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nby20231231_10ka.htm": { "nsprefix": "nby", "nsuri": "http://www.nby.com/20231231", "dts": { "schema": { "local": [ "nby-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "nby-20231231_def.xml" ] }, "labelLink": { "local": [ "nby-20231231_lab.xml" ] }, "presentationLink": { "local": [ "nby-20231231_pre.xml" ] }, "inline": { "local": [ "nby20231231_10ka.htm" ] } }, "keyStandard": 38, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 0, "elementCount": 42, "unitCount": 2, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 38 }, "report": { "R1": { "role": "http://www.nby.com/20231231/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d202410KA", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20231231_10ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d202410KA", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20231231_10ka.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r3", "r4", "r5" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r3", "r4", "r5" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r3", "r4", "r5" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r3", "r4", "r5" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Financial Statement Error Correction Flag", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r3", "r4", "r5", "r7" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Common Stock Shares, Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Interactive Data, Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r8" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r9" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r3", "r4", "r5" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.nby.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" } } } ZIP 19 0001437749-24-009990-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-009990-xbrl.zip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nby20231231_10ka_htm.xml IDEA: XBRL DOCUMENT 0001389545 2023-01-01 2023-12-31 0001389545 2023-06-30 0001389545 2024-03-21 iso4217:USD shares true 0001389545 10-K/A true 2023-12-31 --12-31 FY 2023 false 001-33678 NOVABAY PHARMACEUTICALS, INC. DE 68-0454536 2000 Powell Street, Suite 1150 Emeryville CA 94608 510 899-8800 Common Stock NBY NYSE No No Yes Yes false Non-accelerated Filer true false false false 3050485 30098150 100 WithumSmith+Brown, PC San Francisco, California This Amendment No. 1 on Form 10-K/A (this “Amendment”) amends the Annual Report on Form 10-K of NovaBay Pharmaceuticals, Inc. for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 26, 2024 (the “Original Filing”). Exhibit 4.1 (Description of Securities) (the “Description of Securities”) was inadvertently omitted in the Original Filing.   This Amendment is being filed solely to file the Description of Securities. No other changes were made to the Original Filing. Further, no attempt has been made in this Amendment to modify or update the other disclosures presented in the Original Filing. This Amendment does not reflect events occurring after the filing of the Form 10-K (i.e., occurring after March 26, 2024) or modify or update those disclosures that may be affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the Original Filing and the registrant’s other filings with the Securities and Exchange Commission.   In accordance with Rule 12b-15 of the Securities Exchange Act of 1934, as amended, this Amendment includes new certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, as amended, dated as of the filing date of this Amendment.